• A G Turkina, E V Domracheva, A V Vorontsova, E A Aseeva, O Iu Vinogradova, O V Stakhina, G A Gusarova, O A Diagileva, E A Semenova, M V Vakhrusheva, T I Kolosheĭnova, E M Abakumov, E Iu Chelysheva, S R Goriacheva, T V Ivanova, E S Zakharova, L Iu Kolosova, A V Zakharova, I N Naumova, L V Diachenko, S M Kulikov, L G Kovaleva, and N D Khoroshko.
• Terapevt Arkh. 2009 Jan 1; 81 (7): 29-36.

AimTo analyse clinical implications of chromosome 8 trisomy in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia (CML) treated with inhibitors of tyrosinkinases (ITK).Material And MethodsA total of 386 patients with CML (chronic phase--288, acceleration phase--77) received imatinib (400-800 mg/day). Because of resistance and/or intolerance some patients were switched to ITK II (nilotinib, dasatinib, bozutinib). This study included 8 CML patients (7 in a chronic phase, 1 in acceleration phase) treated with BCR-ABL ITK inhibitors of the first (imatinib) and the second line (ITK-II). The standard cytogenetic examination, on demand--investigation of the interphase nuclei with FISH, in some cases morphological, cytochemical and histological examinations of the bone marrow were made.ResultsThe existence of a Ph-negative clone with trisomy of chromosome 8 had no negative effect on the course of the disease. The patients showed a stable hematological and cytogenetic response and no need in changing treatment policy. In long-term follow-up Ph-negative clone with trisomy of the chromosome 8 persisted without a clear trend to rise in most patients.ConclusionDetection of a Ph-negative clone with chromosome 8 trisomy at early stages suggests parallel existence of Ph-positive and Ph-negative clones. None of the patients had myelodisplasia.

37 keywords...

hide…